INOZYME PHARMA, INC. Research and Development Expense
INOZYME PHARMA, INC. reported Research and Development Expense of $20.38 million for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2025-05-14
- INOZYME PHARMA, INC. research and development expense for the quarter ending 2025-03-31 was $20.38M, a 6.63% increase year-over-year.
- INOZYME PHARMA, INC. research and development expense for the quarter ending 2024-12-31 was $22.47M, a 24.97% increase year-over-year.
- INOZYME PHARMA, INC. research and development expense for the quarter ending 2024-09-30 was $19.89M, a 49.09% increase year-over-year.
- INOZYME PHARMA, INC. research and development expense for the quarter ending 2024-06-30 was $21.76M, a 86.51% increase year-over-year.
- INOZYME PHARMA, INC. research and development expense for fiscal 2024 was $83.23M, a 51.75% increase from fiscal 2023.
- INOZYME PHARMA, INC. research and development expense for fiscal 2023 was $54.85M, a 14.63% increase from fiscal 2022.
- INOZYME PHARMA, INC. research and development expense for fiscal 2022 was $47.85M, a 26.85% increase from fiscal 2021.
- INOZYME PHARMA, INC. research and development expense for fiscal 2021 was $37.72M, a 18.87% decline from fiscal 2020.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2025-03-31 | $20.38M 10-Q · filed 2025-05-14 | $42.85M derived: sum of 2 quarters · filed 2025-05-14 | $62.74M derived: sum of 3 quarters · filed 2025-05-14 | $84.50M derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-12-31 | $22.47M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $42.36M derived: sum of 2 quarters · filed 2025-03-10 | $64.12M derived: sum of 3 quarters · filed 2025-03-10 | $83.23M 10-K · filed 2025-03-10 |
| 2024-09-30 | $19.89M 10-Q · filed 2024-11-05 | $41.65M derived: sum of 2 quarters · filed 2024-11-05 | $60.76M 10-Q · filed 2024-11-05 | $78.74M derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-06-30 | $21.76M 10-Q · filed 2024-08-06 | $40.87M 10-Q · filed 2024-08-06 | $58.85M derived: sum of 3 quarters · filed 2025-05-14 | $72.19M derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-03-31 | $19.11M 10-Q · filed 2025-05-14 | $37.09M derived: sum of 2 quarters · filed 2025-05-14 | $50.44M derived: sum of 3 quarters · filed 2025-05-14 | $62.10M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $17.98M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $31.32M derived: sum of 2 quarters · filed 2025-03-10 | $42.99M derived: sum of 3 quarters · filed 2025-03-10 | $54.85M 10-K · filed 2025-03-10 |
| 2023-09-30 | $13.34M 10-Q · filed 2024-11-05 | $25.01M derived: sum of 2 quarters · filed 2024-11-05 | $36.86M 10-Q · filed 2024-11-05 | $50.70M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $11.67M 10-Q · filed 2024-08-06 | $23.52M 10-Q · filed 2024-08-06 | $37.36M derived: sum of 3 quarters · filed 2024-08-06 | $49.55M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $11.86M 10-Q · filed 2024-05-07 | $25.69M derived: sum of 2 quarters · filed 2024-05-07 | $37.88M derived: sum of 3 quarters · filed 2024-05-07 | $47.89M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $13.84M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $26.03M derived: sum of 2 quarters · filed 2024-03-12 | $36.03M derived: sum of 3 quarters · filed 2024-03-12 | $47.85M 10-K · filed 2024-03-12 |
| 2022-09-30 | $12.19M 10-Q · filed 2023-11-07 | $22.20M derived: sum of 2 quarters · filed 2023-11-07 | $34.01M 10-Q · filed 2023-11-07 | $47.56M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $10.01M 10-Q · filed 2023-08-08 | $21.82M 10-Q · filed 2023-08-08 | $35.37M derived: sum of 3 quarters · filed 2023-08-08 | $44.72M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $11.81M 10-Q · filed 2023-05-09 | $25.36M derived: sum of 2 quarters · filed 2023-05-09 | $34.71M derived: sum of 3 quarters · filed 2023-05-09 | $42.93M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $13.55M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $22.90M derived: sum of 2 quarters · filed 2023-03-22 | $31.12M derived: sum of 3 quarters · filed 2023-03-22 | $37.72M 10-K · filed 2023-03-22 |
| 2021-09-30 | $9.35M 10-Q · filed 2022-11-10 | $17.57M derived: sum of 2 quarters · filed 2022-11-10 | $24.17M 10-Q · filed 2022-11-10 | $31.20M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $8.22M 10-Q · filed 2022-08-15 | $14.82M 10-Q · filed 2022-08-15 | $21.86M derived: sum of 3 quarters · filed 2022-08-15 | $47.03M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $6.60M 10-Q · filed 2022-05-10 | $13.64M derived: sum of 2 quarters · filed 2022-05-10 | $38.81M derived: sum of 3 quarters · filed 2022-05-10 | $46.69M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $7.04M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $32.21M derived: sum of 2 quarters · filed 2022-03-15 | $40.09M derived: sum of 3 quarters · filed 2022-03-15 | $46.49M 10-K · filed 2022-03-15 |
| 2020-09-30 | $25.17M 10-Q · filed 2021-11-09 | $33.05M derived: sum of 2 quarters · filed 2021-11-09 | $39.46M 10-Q · filed 2021-11-09 | $44.74M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $7.88M 10-Q · filed 2021-08-11 | $14.28M 10-Q · filed 2021-08-11 | $19.56M derived: sum of 3 quarters · filed 2021-08-11 | $22.88M derived: sum of 4 quarters · filed 2021-08-11 |
| 2020-03-31 | $6.41M 10-Q · filed 2021-05-12 | $11.69M derived: sum of 2 quarters · filed 2021-05-12 | $15.00M derived: sum of 3 quarters · filed 2021-05-12 | $18.49M derived: sum of 4 quarters · filed 2021-05-12 |
| 2019-12-31 | $5.28M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $8.60M derived: sum of 2 quarters · filed 2021-03-25 | $12.09M derived: sum of 3 quarters · filed 2021-03-25 | $16.22M 10-K · filed 2021-03-25 |
| 2019-09-30 | $3.32M 10-Q · filed 2020-11-12 | $6.81M derived: sum of 2 quarters · filed 2020-11-12 | $10.94M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $3.49M 10-Q · filed 2020-09-03 | $7.62M 10-Q · filed 2020-09-03 |